Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER Positive, Her2 Negative Breast Cancer Patients”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 0 results

Not applicableUnknownNCT02875951
What this trial is testing

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer

Who this might be right for
ER Positive, HER2 Negative Breast Cancer Neoplasms
KU Leuven 100
Testing effectiveness (Phase 2)Looking for participantsNCT06259929
What this trial is testing

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Fondazione Oncotech 51
Not applicableWithdrawnNCT03080428
What this trial is testing

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
ER-positive Her2-negative Early Breast Cancer
UNICANCER
Testing effectiveness (Phase 2)Study completedNCT03628066
What this trial is testing

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06247995
What this trial is testing

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 20
Large-scale testing (Phase 3)Active Not RecruitingNCT02488967
What this trial is testing

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaEstrogen Receptor NegativeHER2/Neu Negative+7 more
NRG Oncology 782